Physician profile
Stephen H Kimura
NPI 1891776563
$15,164.69
in general payments reported to CMS, 2019-2025
34 companies · $2,977 in 2025
The $2,977 reported for 2025 was more than what 80% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $1,540 · 2021: $2,233 · 2022: $1,810 · 2023: $2,362 · 2024: $2,800 · 2025: $2,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,836 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,835.51 |
| Education | $303.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,172.09 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $2,159.77 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $1,599.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,599.36 | 2019-2025 | Trelegy Ellipta, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $1,468.86 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Genentech USA, INC. | $738.95 | 2019-2025 | Xolair |
| Amgen INC. | $735.93 | 2021-2025 | Tezspire |
| Octapharma USA, INC. | $567.58 | 2020-2024 | Cutaquig |
| Grifols USA, LLC | $566.60 | 2019-2024 | Xembify |
| Optinose US, INC. | $448.43 | 2019-2025 | |
| Kaleo, INC. | $336.47 | 2020-2023 | Auvi-Q |
| Csl Behring | $331.37 | 2024-2025 | Haegarda, Hizentra |
| Pfizer INC. | $273.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $272.45 | 2019-2025 | |
| Abbvie INC. | $261.22 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $237.96 | 2022-2025 | Ayvakit |
| Shire North American Group INC | $233.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.77 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $209.38 | 2022-2025 | Orladeyo |
| Incyte Corporation | $125.18 | 2021-2025 | Opzelura |
| Pharming Healthcare, INC. | $111.44 | 2019-2025 | Ruconest |
| Aimmune Therapeutics, INC. | $98.50 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 | |
| Lilly USA, LLC | $46.67 | 2024-2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $45.67 | 2023-2024 | Ryaltris |
| Leo Pharma INC. | $40.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $38.46 | 2021 | |
| Merck Sharp & Dohme LLC | $33.70 | 2021-2023 | |
| Adma Biomanufacturing LLC | $32.69 | 2020-2021 | |
| Tersera Therapeutics LLC | $25.80 | 2021 | |
| Ionis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Horizon Therapeutics Plc | $19.77 | 2021 | |
| Organon LLC | $12.99 | 2025 | |
| Alk-Abello, INC | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kimura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.